Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

Blood (2024) 144 (Supplement 1): 338.

https://doi.org/10.1182/blood-2024-199868

Published: 2024

Journal Articles

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

Blood (2023) 142 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2023-178551

Published: 2023

Journal Articles

The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin–transferrin receptor 1 axis

Blood (2023) 142 (4): 352–364.

https://doi.org/10.1182/blood.2022018597

Published: 2023

Includes: Supplemental data

Journal Articles

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Blood (2023) 141 (17): 2114–2126.

https://doi.org/10.1182/blood.2022017333

Published: 2023

Includes: Supplemental data

Journal Articles

Allogeneic Donor T Cells Directly Attack Renal Endothelial and Epithelial Cells in Mice

Masahiro Miyata, Eri Matsuki, Yuka Hosokawa, Masahiro Suto, Kazunobu Ichikawa, Dan Peltier, Kenichi Ishizawa, Masafumi Watanabe, Tomomi Toubai

Blood (2022) 140 (Supplement 1): 7332–7333.

https://doi.org/10.1182/blood-2022-158676

Published: 2022

Journal Articles

The Absence of NLRP6 in Donor T Cells Exacerbates Gvhd

Masahiro Suto, Eri Matsuki, Masahiro Miyata, Erika Sekiguchi, Hiroya Tamaki, Isao Tawara, Daniel Peltier, Grace Chen, Kenichi Ishizawa, Pavan Reddy, Tomomi Toubai

Blood (2021) 138 (Supplement 1): 2766.

https://doi.org/10.1182/blood-2021-152089

Published: 2021

Journal Articles

Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study

Takaaki Ono, Masayuki Hino, Itaru Matsumura, Shin Fujisawa, Kenichi Ishizawa, Emiko Sakaida, Naohiro Sekiguchi, Chiho Ono, Mana Aizawa, Yusuke Tanetsugu, Yuichiro Koide, Naoto Takahashi

Blood (2021) 138 (Supplement 1): 2557.

https://doi.org/10.1182/blood-2021-145164

Published: 2021

Journal Articles

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Blood (2021) 138 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2021-145483

Published: 2021

Journal Articles

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

Brian A Jonas, MD PhD, Courtney D. Dinardo, MDMSc, Nicola Fracchiolla, Alexander Pristupa, MD, Kenichi Ishizawa, MD PhD, Jie Jin, MD PhD, Marina Konopleva, MD PhD, Yishai Ofran, Pau Montesinos, MD PhD, Tibor Kovacsovics, MD, Jun-Ho Jang, MD, Hagop M. Kantarjian, MD, Wan-Jen Hong, MD, Yinghui Duan, PhD, William Ainsworth, Jalaja Potluri, MD, Michael Werner, Anders Erik Svensson, MD, Keith W. Pratz, MD

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-134850

Published: 2020

Journal Articles

NLRP6 in Donor T Cells Separately Regulates CD4 and CD8 Mediated Graft-Versus-Host Disease in Experimental Murine BMT

Masahiro Suto, Eri Matsuki, MD, Erika Sekiguchi, Hiroya Tamaki, MD PhD, Isao Tawara, MD PhD, Grace Chen, MD PhD, Kenichi Ishizawa, MD PhD, Pavan Reddy, Tomomi Toubai

Blood (2019) 134 (Supplement_1): 1926.

https://doi.org/10.1182/blood-2019-123875

Published: 2019

Journal Articles

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Naoto Takahashi, MD PhD, Itaru Matsumura, MD PhD, Shin Fujisawa, MD, Kenichi Ishizawa, MD PhD, Takaaki ONO, MD PhD, Emiko Sakaida, MD PhD, Naohiro Sekiguchi, MD PhD, Yusuke Tanetsugu, Kei Fukuhara, Masayuki Ohkura, Yuichiro Koide, Masayuki Hino, MD PhD

Blood (2019) 134 (Supplement_1): 4159.

https://doi.org/10.1182/blood-2019-121809

Published: 2019

Journal Articles

Donor T Cell Independent Mechanism Is Critical for Mediating Steroid Refractory Gvhd in Murine Models

Tomomi Toubai, MDPhD, Corrine Rossi, Isao Tawara, MD PhD, Chen Liu, MD PhD, Cynthia Zajac, Katherine Oravecz-Wilson, BS, MS, Dan Peltier, MD, Yaping Sun, MD PhD MS, Hideaki Fujiwara, MD, Mary Mansour Riwes, DO, Israel Henig, MD, Stephanie Kim, BS, Masahiro Suto, Kenichi Ishizawa, MD PhD, Pavan Reddy, MD

Blood (2018) 132 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2018-99-114634

Published: 2018

Journal Articles

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Blood (2018) 132 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2018-99-110201

Published: 2018

Journal Articles

Role of GATA2 in the Maintenance of the Bone Marrow Microenvironment

Shin Hasegawa, Tohru Fujiwara, MD PhD, Yoko Okitsu, MD PhD, Hiroki Kato, MD, PhD, Yuki Sato, Noriko Fukuhara, MD PhD, Yasushi Onishi, MD PhD, Kenichi Ishizawa, Ritsuko Shimizu, MD PhD, Masayuki Yamamoto, MD PhD, Hideo Harigae, MD

Blood (2017) 130 (Supplement 1): 3781.

https://doi.org/10.1182/blood.V130.Suppl_1.3781.3781

Published: 2017

Journal Articles

Phase I/II Multicenter Study of Romidepsin in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Blood (2016) 128 (22): 3012.

https://doi.org/10.1182/blood.V128.22.3012.3012

Published: 2016

Journal Articles

Multicenter, Open-Label Phase I Clinical Study of Oral Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: Tolerability, Efficacy, and Pharmacokinetic Profiles

Kenichi Ishizawa, MD PhD, Kensuke Usuki, MD PhD, Kiyoshi Ando, MD PhD, Yasunori Ueda, MD PhD, Toru Kiguchi, MD PhD, Naokuni Uike, MD PhD, Yasushi Onishi, MD PhD, Hiroatsu Iida, MD PhD

Blood (2016) 128 (22): 5538.

https://doi.org/10.1182/blood.V128.22.5538.5538

Published: 2016

Journal Articles

GATA2 regulates dendritic cell differentiation

Koichi Onodera, Tohru Fujiwara, Yasushi Onishi, Ari Itoh-Nakadai, Yoko Okitsu, Noriko Fukuhara, Kenichi Ishizawa, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

Blood (2016) 128 (4): 508–518.

https://doi.org/10.1182/blood-2016-02-698118

Published: 2016

Includes: Supplemental data

Journal Articles

GATA-2 Regulates Dendritic Cell Differentiation

Koichi Onodera, MD, PhD, Tohru Fujiwara, MD, PhD, Yasushi Onishi, MD, PhD, Ari Itoh-Nakadai, PhD, Yoko Okitsu, MD PhD, Noriko Fukuhara, MD PhD, Kenichi Ishizawa, MD, PhD, Ritsuko Shimizu, MD, PhD, Masayuki Yamamoto, MD, PhD, Hideo Harigae, MD, PhD

Blood (2015) 126 (23): 2382.

https://doi.org/10.1182/blood.V126.23.2382.2382

Published: 2015

Journal Articles

Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma

Hiroshi Fujiwara, MD PhD, Takashi Ishida, MD PhD, Kisato Nosaka, MD PhD, Naoya Taira, MD, Yasunobu Abe, MD PhD, Yoshitaka Imaizumi, MD PhD, Yukiyoshi Moriuchi, MD, Tatsuro Jo, MD PhD, Kenichi Ishizawa, MD, PhD, Kensei Tobinai, MD PhD, Kunihiro Tsukasaki, MD PhD, Shigeki Ito, MD PhD, Makoto Yoshimitsu, Maki Otsuka, Michinori Ogura, MD, Shuichi Midorikawa, PhD, Wanda Ruiz, PhD, Tomoko Ohtsu, MD

Blood (2015) 126 (23): 181.

https://doi.org/10.1182/blood.V126.23.181.181

Published: 2015

Journal Articles

Current Clinico-Epidemiological Characteristics of Adult T-Cell Leukemia-Lymphoma (ATL) Based on the 11th Nationwide Survey in Japan

Kisato Nosaka, MD PhD, Masako Iwanaga, MD, PhD, Kenichi Ishizawa, MD, PhD, Yoji Ishida, MD, PhD, Kaoru Uchimaru, MD, PhD, Kenji Ishitsuka, MD, PhD, Masahiro Amano, MD,PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD, Naokuni Uike, MD, PhD, Atae Utsunomiya, MD, PhD, Koichi Ohshima, MD PhD, Kazuhiro Kawai, MD, PhD, Junji Tanaka, MD, PhD, Yoshiki Tokura, MD, PhD, Kensei Tobinai, MD PhD, Toshiki Watanabe, MD, PhD, Kunihiro Tsukasaki, MD, PhD

Blood (2015) 126 (23): 5034.

https://doi.org/10.1182/blood.V126.23.5034.5034

Published: 2015

NARROW

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin–transferrin receptor 1 axis

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Allogeneic Donor T Cells Directly Attack Renal Endothelial and Epithelial Cells in Mice

The Absence of NLRP6 in Donor T Cells Exacerbates Gvhd

Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

NLRP6 in Donor T Cells Separately Regulates CD4 and CD8 Mediated Graft-Versus-Host Disease in Experimental Murine BMT

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Donor T Cell Independent Mechanism Is Critical for Mediating Steroid Refractory Gvhd in Murine Models

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Role of GATA2 in the Maintenance of the Bone Marrow Microenvironment

Phase I/II Multicenter Study of Romidepsin in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Multicenter, Open-Label Phase I Clinical Study of Oral Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: Tolerability, Efficacy, and Pharmacokinetic Profiles

GATA2 regulates dendritic cell differentiation

GATA-2 Regulates Dendritic Cell Differentiation

Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma

Current Clinico-Epidemiological Characteristics of Adult T-Cell Leukemia-Lymphoma (ATL) Based on the 11th Nationwide Survey in Japan

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only